Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two strengths. The approval expands Biocon’s US immunology portfolio, with Yesintek used to treat conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two strengths. The approval expands Biocon’s US immunology portfolio, with Yesintek used to treat conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
<iframe src="https://hindustansphere.com/embed/cluster/6aec5fd90bc85f5c21a75e60106d3658b0910851" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Biocon shares rise 2% after USFDA approval for Yesintek single-dose prefilled autoinjector"></iframe>
